Although Margetuximab is an example of a tumor-targeting mAb with reduced FcγRIIB interaction, it should be noted that there is growing evidence that the efficacy of immune checkpoint agonistic mAbs benefits from FcγRIIB crosslinking [44,88]. The gene discussed is FCGR2B; the disease is neoplasm.